ArticleEuropean journal of nuclear medicine and molecular imaging2021
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
184 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review.Annals of nuclear medicine · 2025Pooled it
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- Trial
- Trial
- Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021Trial
- Article
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
- Automated lesion tracking and treatment response classification on [European journal of nuclear medicine and molecular imaging · 2026Article
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.European journal of nuclear medicine and molecular imaging · 2026Article
- Imaging and Clinical Correlates of [Biomedicines · 2026Article
- Reference tissue uptake of [18F]PSMA-1007 in positron emission tomography of recurrent prostate cancer.European radiology · 2026Article
- Diagnostic impact of interpretation criteria for [European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight?Annals of nuclear medicine · 2026Review
- Article
124 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
rationaleThe development of consensus guidelines for interpretation of Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide more consistent reports in clinical practice. The standardization of PSMA-PET interpretation may also contribute to increasing the data reproducibility within clinical trials. Finally, guidelines in PSMA-PET interpretation are needed to communicate the exact location of findings to referring physicians, to support clinician therapeutic management decisions.
methodsA panel of worldwide experts in PSMA-PET was established. Panelists were selected based on their expertise and publication record in the diagnosis or treatment of PCa, in their involvement in clinical guidelines and according to their expertise in the clinical application of radiolabeled PSMA inhibitors. Panelists were actively involved in all stages of a modified, nonanonymous, Delphi consensus process.
resultsAccording to the findings obtained by modified Delphi consensus process, panelist recommendations were implemented in a structured report for PSMA-PET.
conclusionsThe E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for PSMA-PET in prostate cancer and to harmonize diagnostic interpretation criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.